Immutep (Immutep) Payments to Suppliers for Goods and Services

: $-34.10 Mil (TTM As of Dec. 2023)

View and export this data going back to 1988. Start your Free Trial

Immutep's Payments to Suppliers for Goods and Services for the three months ended in Dec. 2023 was $-9.80 Mil.

Immutep's Payments to Suppliers for Goods and Services for the trailing twelve months (TTM) ended in Dec. 2023 was $-34.10 Mil.

Immutep Payments to Suppliers for Goods and Services Historical Data

The historical data trend for Immutep's Payments to Suppliers for Goods and Services can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immutep Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Payments to Suppliers for Goods and Services

-13.58

-18.34

-14.92

-23.78

-26.84

Immutep Quarterly Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Payments to Suppliers for Goods and Services																-5.89	-7.69	-10.36	-6.25	-9.80

Immutep Payments to Suppliers for Goods and Services Calculation

A company's cash flow from operations for a time period can be determined using either the direct or indirect method. The indirect method modifies the operating section from accrual accounting to a cash basis by taking the net income generated in a period and adding or subtracting changes in the asset and liability accounts to determine the implied cash flow. However, the direct method uses actual cash inflows and outflows from the company's operations directly. Payments to Suppliers for Goods and Services represents cash paid to suppliers when purchasing goods or services by the company in the direct cash flow method.

Payments to Suppliers for Goods and Services for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-34.10 Mil.

Immutep (Immutep) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immutep Ltd (NAS:IMMP) » Definitions » Payments to Suppliers for Goods and Services

Comparable Companies

Traded in Other Exchanges

PRRUF:USA YP1B:Germany IMM:Australia

Address

264 George Street, Level 33, Australia Square, Sydney, NSW, AUS, 2000

Website

https://www.immutep.com

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trails, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia and derives the majority of the revenue from the sale of the products.